Focus: Trevi Therapeutics is a public biotech company focused on small-molecule therapies for respiratory, dermatology, and neurology indications. The company operates as a clinical-stage player with a concentrated pipeline centered on nalbuphine ER formulations.
Profile data last refreshed 4h ago · AI intelligence enriched 2mo ago
Suitable for early-career scientists or commercial professionals seeking equity upside and direct ownership of clinical assets, but not for those prioritizing stability or rapid team scaling.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Trevi Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Trevi Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
+1 more
Trevi Therapeutics (TRVI) Edges Lower 1.07% as Shares Consolidate Between Key Support and Resistance - ETF Outflow Streak - siam.in
Trevi Therapeutics (TRVI) Edges Lower 1.07% as Shares Consolidate Between Key Support and Resistance - ETF Outflow Streak siam.in
Trevi Therapeutics to Participate in Upcoming September Conferences - Yahoo Finance
Trevi Therapeutics to Participate in Upcoming September Conferences Yahoo Finance
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026 - GlobeNewswire
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026 GlobeNewswire
Trevi Therapeutics advances with Haduvio to tar... - Pluang
Trevi Therapeutics advances with Haduvio to tar... Pluang
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform (NASDAQ:TRVI) - Seeking Alpha
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform (NASDAQ:TRVI) Seeking Alpha
Trevi Therapeutics (TRVI) Could Be 34% Undervalued On Wider Losses And Shelf Filing - simplywall.st
Trevi Therapeutics (TRVI) Could Be 34% Undervalued On Wider Losses And Shelf Filing simplywall.st
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo